BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 18295609)

  • 1. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
    Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
    Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
    Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
    Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
    Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
    J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening and Elucidation of Selected Natural Compounds for Anti- Alzheimer's Potential Targeting BACE-1 Enzyme: A Case Computational Study.
    Ahmad SS; Akhtar S; Danish Rizvi SM; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Arif JM
    Curr Comput Aided Drug Des; 2017 Nov; 13(4):311-318. PubMed ID: 28413992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of a novel membrane assay for full-length BACE-1 at pH 6.0.
    Saric A; Brügge Lz; Müller-Pompalla D; Rysiok T; Ousson S; Permanne B; Quattropani A; Busch M; Beher D; Hussain I
    J Biomol Screen; 2013 Mar; 18(3):277-85. PubMed ID: 23023105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
    Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
    Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential of natural product vs neurodegenerative disorders: In silico study of artoflavanocoumarin as BACE-1 inhibitor.
    Razzaghi-Asl N; Karimi A; Ebadi A
    Comput Biol Chem; 2018 Dec; 77():307-317. PubMed ID: 30445338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
    Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
    Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway.
    Ali MY; Jannat S; Edraki N; Das S; Chang WK; Kim HC; Park SK; Chang MS
    Chem Biol Interact; 2019 Aug; 309():108707. PubMed ID: 31194956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.
    John S; Thangapandian S; Sakkiah S; Lee KW
    BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavonoids as BACE1 inhibitors: QSAR modelling, screening and in vitro evaluation.
    Das S; Majumder T; Sarkar A; Mukherjee P; Basu S
    Int J Biol Macromol; 2020 Dec; 165(Pt A):1323-1330. PubMed ID: 33010267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease in the Generation of Amyloid-β Due to Salvianolic Acid B by Modulating BACE1 Activity.
    Durairajan SSK; Chirasani VR; Shetty SG; Iyaswamy A; Malampati S; Song J; Liu L; Huang J; Senapati S; Li M
    Curr Alzheimer Res; 2017; 14(11):1229-1237. PubMed ID: 28413985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease.
    Lee J; Samson AAS; Song JM
    Anal Chim Acta; 2018 Aug; 1022():89-95. PubMed ID: 29729742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human beta-secretase (BACE) and BACE inhibitors: progress report.
    John V
    Curr Top Med Chem; 2006; 6(6):569-78. PubMed ID: 16712492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
    Semighini EP
    Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
    Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease.
    Huang WH; Sheng R; Hu YZ
    Curr Med Chem; 2009; 16(14):1806-20. PubMed ID: 19442147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.